Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report of cardiovascular toxicity with serial echocardiographic evaluation.
The most serious side effects of recombinant interleukin-2 (rIL-2) and recombinant interferon-alpha (rIFN alpha) immunotherapy are cardiovascular disturbances, including systemic hypotension, left-ventricular dysfunction and pulmonary edema. We present a 25-year-old female who developed reversible cardiogenic shock during intermediate dose rIL-2 and low dose rIFN alpha therapy. Rapid clinical improvement occurred after intravenous fluid and dopamine support. A serial echocardiographic evaluation, which has not been described previously in this setting, is reported.
Schechter
D
D
Department of Cardiology, Hadassah University Hospital, Jerusalem, Israel.
Nagler
A
A
Ackerstein
A
A
Nassar
H
H
Admon
D
D
Naparstek
E
E
Rein
A J
AJ
D000328:Adult; D016026:Bone Marrow Transplantation; D003131:Combined Modality Therapy; D004452:Echocardiography; D005260:Female; D006689:Hodgkin Disease / Q000628:therapy; D006801:Humans; D007370:Interferon Type I / Q000009:adverse effects* / Q000627:therapeutic use; D007376:Interleukin-2 / Q000009:adverse effects* / Q000627:therapeutic use; D011994:Recombinant Proteins; D012770:Shock, Cardiogenic / Q000000981:diagnostic imaging / Q000209:etiology*
D007370:Interferon Type I; D007376:Interleukin-2; D011994:Recombinant Proteins